The outcomes of the ToGA trial by Bang et al. [20] comprised the initial evidence to demonstrate that combination chemotherapy with trastuzumab improves the survival rate of HER-2-positive advanced gastric cancer patients. Here, ERBB2 is linked to gastric cancer.